Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMF16CU)

• Drug Name: Vicasinabin Drug Info
• Synonyms: Vicasinabin; Vicasinabin [INN]; QJ8UO6C05M; RG7774; 1433361-02-4; RG-7774; (S)-1-(5-tert-Butyl-3-((1-methyl-1H-tetrazol-5-yl)methyl)-3H-(1,2,3)triazolo-(4,5-d)pyrimidin-7-yl)pyrrolidin-3-ol; 3-Pyrrolidinol, 1-(5-(1,1-dimethylethyl)-3-((1-methyl-1H-tetrazol-5-yl)methyl)-3H-1,2,3-triazolo(4,5-d)pyrimidin-7-yl)-, (3S)-; 3-Pyrrolidinol, 1-[5-(1,1-dimethylethyl)-3-[(1-methyl-1H-tetrazol-5-yl)methyl]-3H-1,2,3-triazolo[4,5-d]pyrimidin-7-yl]-, (3S)-; VICASINABIN [USAN]; UNII-QJ8UO6C05M; SCHEMBL14912040; GTPL11890; EX-A8231; AKOS040756804; Example 151 [WO2013068306A1]; HY-145604; RO6868847; CS-0376695; RO-6868847; (3S)-1-(5-(1,1-Dimethylethyl)-3-((1-methyl-1H-tetrazol-5-yl)methyl)-3H-1,2,3-triazolo(4,5-d)pyrimidin-7-yl)-3-pyrrolidinol; (3S)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol; (3S)-1-{5-tert-butyl-3-[(1-methyl-1H-tetrazol-5-yl)methyl]-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl{pyrrolidin-3-ol

Indication

Disease Entry	ICD 11	Status	REF
Diabetic retinopathy	9B71.0	Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 86296048
  TTD Drug ID: DMF16CU

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cannabinoid receptor 2 (CB2)	TTMSFAW	CNR2_HUMAN	Agonist	[1]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Cannabinoid receptor 2 (CB2)	DTT	CNR2	7.037	6.733	6.944	7.163

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

• The Studied Disease: Diabetic retinopathy
• ICD Disease Classification: 9B71.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Cannabinoid receptor 2 (CB2)	DTT	CNR2	3.82E-02	-0.43	-1.18

References

• [1] Clinical pipeline report, company report or official report of Roche